Stablecoin issuer Circle tops revenue estimate in first quarterly result since IPO
Higher circulation of its USDC stablecoin and stronger subscription services helped the New York-based company cement a rally that has pushed its stock to more than five times its initial public offering price.
Stablecoins, which are digital tokens backed by low-risk assets such as the U.S. dollar or Treasuries, have drawn increasing investor attention, especially since the Genius Act was passed last month.
The momentum has helped companies such as Circle, which issues USDC - the second-biggest stablecoin by market value after Tether.
After "our IPO and the Genius Act, we're seeing an acceleration of interest, with major institutions all leaning in," Chief Financial Officer Jeremy Fox-Geen said in an interview.
USDC in circulation grew 90% as of June 30, compared to a year earlier. Circle expects it to grow at a compounded annual rate of 40% through the years.
The token was also being used for cross-border transactions, including remittances both between individuals and businesses, CEO Jeremy Allaire said.
The company's revenue and reserve income grew 53% year-over-year to $658 million, thanks to a jump in the interest it earns from the cash and short-term investments backing its USDC stablecoins. Revenue from subscription and services also rose, Circle said.
Analysts were expecting revenues of $644.7 million, according to estimates compiled by LSEG.
The company's net loss was $482 million, primarily due to two non-cash charges related to its IPO, including costs for employee stock awards that vested when the company went public and a higher valuation of its convertible debt following a rise in its share price.
Circle on Tuesday also said it will roll out Arc, a public blockchain designed specifically for stablecoin transactions, this fall as it pushes to build the technological infrastructure for digital payments.
"They're really trying to become the pillar of stablecoins in the U.S.," said David Bartosiak, stock strategist at Zacks Investment Research.
"Circle can use what they have already done to establish themselves as a trusted mover."
However, the company was currently not looking to strike many deals, even as the massive jump in its stock price has given it the ability to do so, CEO Allaire said.
"We're careful and deliberate. I don't think our strategy here is to go try and do big, complex acquisitions to throw additional business lines."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
23 minutes ago
- Daily Mail
Government-run grocery store in Kansas City forced to shut down thanks to rampant shoplifting and empty shelves
A city-run grocery store in Kansas City has been forced to close after rampant shoplifting and years of empty shelves. The Sun Fresh Market abruptly shut its doors on Monday, August 12, with a handwritten sign taped to the entrance, reading: 'Due to unforeseen circumstances beyond our control, we are no longer able to serve residents at this time.' Emmet Pierson Jr., the group's CEO, has repeatedly said that relentless shoplifting and crime in the neighborhood have driven away customers. Just last month, images at the grocery store shared online revealed mostly bare shelves and coolers as well as empty meat, produce and deli departments. Shoppers said the store once held the fresh items they needed, but that it has been mostly empty for the last three months - and that some of the products available appear to be expired. 'The milk, I am scared to buy some,' shopper Michaelle Randolph told KMBC at the time. 'Even the dates, they may have a few days over. I don't want to buy that.' 'It's a rancid odor. I think something is dead or something's gone bad,' added shopper Jon Murphy. The store opened in 2018 in Kansas City as part of a project to bring life back into the city's embattled east side, which did not have a grocery store before. Meanwhile, residents of the area told The Washington Post they are scared to go to the store because of the rampant drug dealing and vagrancy both inside and outside the store. Surveillance cameras inside the store have caught several concerning incidents at the shopping center, including a naked woman walking through the store, a person urinating and a couple fornicating on the lawn of the library in broad daylight. According to local media, the store has received $28,997,400 in taxpayer money through bonds, loans, ordinances and subsidies. But the closure is a major problem for local residents, who have long struggled with limited access to affordable groceries. The next closest options, including Happy Food Center, Family Market, Aldi, and Save A Lot, are all at least a mile away. Ryan Beal, who worked at Sun Fresh, told KCTV the loss will hit the community hard. The the store once held the fresh items they needed, but that it has been mostly empty for the last three months 'We got elders here. We got grandmas taking care of grandkids here. Some people that come from other places cuz they don't want to shop at stores in their neighborhood. This is gonna be a deadzone too.' Longtime customer Jill Beuford said the store's closure will make daily life far more difficult for many residents. 'I really hate to see really leave the area because so many people, they live around here,' she told the outlet. 'Walking distance where they can come to a store that's close to the community to where they can get to.'
Reuters
23 minutes ago
- Reuters
Citi hires bankers for private credit in North America, tech in Europe
NEW YORK, Aug 13 (Reuters) - Citigroup hired two senior investment bankers this week, extending a recruitment drive by its head of banking, Viswas Raghavan. Aashish Dhakad will start in October in New York as head of private credit origination for North America as part of Citi's $25 billion push into private credit with Apollo Global Management. Dhakad, who previously worked at Ares Management and Bank of America, will report to John McAuley for private credit origination and Scott Sartorius and Ryan Williams, Citi's co-heads of leveraged finance on the continent. Separately, Amit Nayyar was appointed the co-head of tech investment banking in the UK, Europe, Middle East and Africa alongside Yishai Fransis, according to a memo seen by Reuters. He will start in the fourth quarter. Nayyar most recently served as JPMorgan Chase's head of EMEA fintech and payments coverage investment banking. He previously worked at Indian payments company Paytm and Goldman Sachs.
Reuters
23 minutes ago
- Reuters
Exclusive: US pharma tariffs likely weeks away as Trump plans for Alaska, sources say
WASHINGTON Aug 13 (Reuters) - The announcement by President Donald Trump's administration of the results of a probe into pharmaceutical imports and new sector-specific U.S. tariffs likely remains weeks away, four official and industry sources said, later than initially promised as he focuses on other matters. Commerce Secretary Howard Lutnick had said in April when the review of whether reliance on foreign drug production threatens U.S. national security was launched that he anticipated that it would conclude between mid-May and mid-June. Global pharmaceutical companies are bracing for the outcome of the investigation, which will usher in sector-specific tariffs that Trump has said could start small and eventually rise to 250%. The Republican president said as recently as last week that his plan relies on phased-in tariffs, giving drugmakers time to increase manufacturing in the United States as he pushes to alter what he says are global trade distortions in many industries. One government official in Europe and a source with knowledge of the White House process, as well as two sources at European drug firms familiar with the process, told Reuters that the report and tariffs announcement was not imminent and likely weeks away. These sources spoke on condition of anonymity. A White House spokesperson, asked about media reporting indicating that the results of the probe could be several weeks away, cautioned that such reports were pure speculation unless confirmed by the White House. The spokesperson declined to give further details about the timing of the pharma probe or one involving semiconductors. The investigation is examining pharmaceutical imports ranging from finished prescription drugs to active pharmaceutical ingredients, called APIs, and other raw materials, with the results to be disclosed in a Commerce Department report. Lutnick said last month the tariff plan that will be based on the report would be completed by the end of July. Lutnick then said on July 29 it would be two more weeks. The investigation was launched under Section 232 of the Trade Expansion Act of 1962. While the investigation is ongoing, the pharmaceutical sector has been exempted from the sweeping tariffs imposed by the Trump administration. The United States has reached bilateral trade deals with the UK, Japan, South Korea and the European Union that promised more favorable terms for their pharma exports than those expected to be levied on the sector globally. A European government official said that an announcement before the end of August appears unlikely but cautioned that the timeline could shift depending on other developments. A source at a European drugmaker said the Trump administration is focused on the U.S.-Russia summit in Alaska on Friday and therefore no announcement is expected this week. The source familiar with the White House process said that announcement is unlikely to come this week given other priorities. That source and one other source said that they expect the Trump administration to announce the results of its national security investigation into semiconductors first, followed by the pharma announcement, putting it a few weeks away. The Section 232 provision authorizes the president to adjust imports - including imposing tariffs - if a category of goods is being imported into the United States in quantities that "threaten or impair the national security." Medical goods historically have been spared from trade wars due to the potential harm to patient access, and drugmakers have said tariffs could undercut other health policy goals outlined by the Trump administration, including lowering drug prices. U.S. tariffs on imported pharmaceutical products would mark the latest in a series of sectoral tariffs announced by the administration, following metals and cars, that some economists have predicted will drive up costs for American consumers.
